Cooperative evolution of mechanisms of β-lactam resistance

Slides:



Advertisements
Similar presentations
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents
K. Kümmerer, A. Henninger  Clinical Microbiology and Infection 
S. Biswas, D. Raoult, J.-M. Rolain  Clinical Microbiology and Infection 
Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina  S.
Defining an extended-spectrum β-lactamase
Approach to diagnosis of infective endocarditis
Herpes zoster in non-hospitalized children
The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey  U. Över, D. Gür, S. Ünal,
Evolution of extended-spectrum β-lactamases by mutation
K. Kümmerer, A. Henninger  Clinical Microbiology and Infection 
The spread of CTX-M-type extended-spectrum β-lactamases
Defining an extended-spectrum β-lactamase
J.-P. Van geertruyden  Clinical Microbiology and Infection 
Use of antimicrobials and resistance in bacteria isolated from blood cultures in a Danish county from 1992 to 1995  Thomas Lund S⊘rensen, Niels Frimodt-M⊘ller,
Hydatid disease Clinical Microbiology and Infection
Antimicrobial peptides: broad-spectrum antibiotics from nature
Crossing the envelope: how cephalosporins reach their targets
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.
In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species  Jacques Dubois, Claude St-Pierre  Clinical.
Holt Hanne M. , Søgaard Per , Gahrn-Hansen Bente  
A. Bryskier  Clinical Microbiology and Infection 
Structure of grepafloxacin relative to activity and safety profile
Vector control: a cornerstone in the malaria elimination campaign
C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins
Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.
β-Lactamases: quality and resistance
Training for the infectious diseases speciality in Norway
Cephalosporins: a pharmacological update
Epidemiology of opportunistic infections in AIDS patients
Laboratory diagnosis and biosafety issues of biological warfare agents
CMI editorial report 2011 Clinical Microbiology and Infection
Sepsis and neutropenia induced by clozapine
Uncommon opportunistic fungi: new nosocomial threats
André Bryskier  Clinical Microbiology and Infection 
In vitro selection of antibiotic resistance in Pseudomonas aeruginosa
M. Aires-de-Sousa  Clinical Microbiology and Infection 
The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey  U. Över, D. Gür, S. Ünal,
Effect of antioxidants on the immune response of Helicobacter pylori
Laboratory diagnosis of Clostridium difficile disease
W.A. Craig  Clinical Microbiology and Infection 
S8 – S47 and O50 – O440 Clinical Microbiology and Infection
Interactions between cytomegalovirus and the p53 tumor suppressor gene in atherosclerotic vascular disease  Inge O. Baas, G. Johan A. Offerhaus, Ralph.
T.M. File  Clinical Microbiology and Infection 
A. Bryskier  Clinical Microbiology and Infection 
Antibacterial drug discovery in the 21st century
Community-acquired pneumonia: epidemiologic and clinical consideration
Abstracts cont. Clinical Microbiology and Infection
Jacques Sirot  Clinical Microbiology and Infection 
Clinical infection services—the Leiden experience
Ethan Rubinstein, Itzhak Levy  Clinical Microbiology and Infection 
Training in infectious diseases—looking to the future
European guidelines for diagnosis and management of patients with suspected herpes simplex encephalitis  Miles Denton, Kevin G Kerr, Fraser Lewis  Clinical.
Clinical Microbiology and Infection
W. Eugene Sanders, Christine C. Sanders 
Overview of cefixime use in community-acquired infections
Panton–Valentine leukocidin-encoding bacteriophage and gene sequence variation in community-associated methicillin-resistant Staphylococcus aureus  J.A.
The atypical pneumonias: clinical diagnosis and importance
Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe  Robert D. Fox  Clinical Microbiology.
Abstracts Clinical Microbiology and Infection
New oral cephalosporins in pediatric community-acquired infections
B.A. Cunha  Clinical Microbiology and Infection 
J.L. Balcázar  Clinical Microbiology and Infection 
G.C. Schito  Clinical Microbiology and Infection 
Gebhard Feierl, Christian Berghold, Theresia Fürpaβ, Egon Marth 
New patterns of HIV-1 resistance during HAART
The future of diagnostic bacteriology
Assessment of the BacT/Alert blood culture system: rapid bacteremia diagnosis with loading throughout the 24 h  Jonas Bengtsson, Martin Wahl, Peter Larsson 
Vincent Calvez, Marc Grandadam  Clinical Microbiology and Infection 
Presentation transcript:

Cooperative evolution of mechanisms of β-lactam resistance A.A. Medeiros  Clinical Microbiology and Infection  Volume 6, Pages 27-33 (January 2000) DOI: 10.1111/j.1469-0691.2000.tb02037.x Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Cartoon showing entry of a β-lactam molecule into the active site cavity of a β-lactamase, hydrolysis of the β-lactam ring end release of the inactivated β-lectam (from [11]). Clinical Microbiology and Infection 2000 6, 27-33DOI: (10.1111/j.1469-0691.2000.tb02037.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Space filling model of the active site cavity of S. aureus PC1 β-lactamase (from [12]). Clinical Microbiology and Infection 2000 6, 27-33DOI: (10.1111/j.1469-0691.2000.tb02037.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 3 Ribbon diagram of the TEM-1 β-lactamase. (Provided by Jim Knox, from [1].) Clinical Microbiology and Infection 2000 6, 27-33DOI: (10.1111/j.1469-0691.2000.tb02037.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 4 (A) Schematic diagram showing the hydrogen bonding network and the amino acid residues of the binding site motifs of a class A β-lactamase. Note the importance of residues E166 and N170 of the omega loop in positioning a water molecule close to sarine-70. (B) Hydrogen bond interactions between the functional groups of a cephalosporin molecule and the side-chains of the amino acid residues of the active site. Note that the NH groups of S70 and A237 hold the carbonyl of the β-lactam ring in the oxyanion pocket. The side-chains of S130 and T235 anchor one end of the molecule and those of N132 and A237 anchor the other (from [1]). Clinical Microbiology and Infection 2000 6, 27-33DOI: (10.1111/j.1469-0691.2000.tb02037.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 5 (A) Ceftazidime in the binding site of TEM-12 (R164S). The broken line between E166 and N170 represents a loosened, more flexible omega loop caused by the R164S mutation that weakens the bonding between R164 and N179 across the neck of the loop (not shown in this diagram). This provides more room for the bulky substituent of ceftazidime. Note that negatively charged side-chains of E104 and E240 repel the terminal carboxyl of the substituent. (B) Ceftazidime in the binding site of TEM-26 (R164S and E104K). The longer, more flexible side-chain of lysine bonds with the carboxyl moiety of the ceftazidime substituent providing an additional anchor (from [1]). Clinical Microbiology and Infection 2000 6, 27-33DOI: (10.1111/j.1469-0691.2000.tb02037.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions